RaySearch Laboratories Dirección

Dirección controles de criterios 3/4

El CEO de RaySearch Laboratories' es Johan Lof , nombrado en Jan 2000, tiene una permanencia de 24.25 años. compensación anual total es SEK6.90M, compuesta por 84.9% salario y 15.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 16.51% de las acciones de la empresa, por valor de €57.09M. La antigüedad media del equipo directivo y de la junta directiva es de 5.5 años y 20.6 años, respectivamente.

Información clave

Johan Lof

Chief Executive Officer (CEO)

kr9.8m

Compensación total

Porcentaje del salario del CEO	66.2%
Permanencia del CEO	24.3yrs
Participación del CEO	16.5%
Permanencia media de la dirección	5.6yrs
Promedio de permanencia en la Junta Directiva	20.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Johan Lof en comparación con los beneficios de RaySearch Laboratories?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	kr101m
Dec 31 2023	kr10m	kr6m	kr82m
Sep 30 2023	n/a	n/a	kr64m
Jun 30 2023	n/a	n/a	kr53m
Mar 31 2023	n/a	n/a	kr22m
Dec 31 2022	kr7m	kr6m	kr24m
Sep 30 2022	n/a	n/a	-kr6m
Jun 30 2022	n/a	n/a	-kr38m
Mar 31 2022	n/a	n/a	-kr35m
Dec 31 2021	kr7m	kr6m	-kr47m
Sep 30 2021	n/a	n/a	-kr46m
Jun 30 2021	n/a	n/a	-kr50m
Mar 31 2021	n/a	n/a	-kr42m
Dec 31 2020	kr7m	kr6m	-kr9m
Sep 30 2020	n/a	n/a	kr24m
Jun 30 2020	n/a	n/a	kr43m
Mar 31 2020	n/a	n/a	kr74m
Dec 31 2019	kr8m	kr6m	kr50m
Sep 30 2019	n/a	n/a	kr64m
Jun 30 2019	n/a	n/a	kr85m
Mar 31 2019	n/a	n/a	kr84m
Dec 31 2018	kr8m	kr5m	kr79m
Sep 30 2018	n/a	n/a	kr118m
Jun 30 2018	n/a	n/a	kr104m
Mar 31 2018	n/a	n/a	kr103m
Dec 31 2017	kr9m	kr5m	kr118m

Compensación vs. Mercado: La compensación total ($USD899.59K) de Johan está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD997.20K).

Compensación vs. Ingresos: La compensación de Johan ha aumentado más de un 20% en el último año.

CEO

Johan Lof (54 yo)

24.3yrs

Permanencia

kr9,758,000

Compensación

Dr. Johan Lof has been the Chief Executive Officer and President of Raysearch Laboratories AB (Publ) since 2000. Dr. Lof serves as the Chief Executive Officer of RaySearch Medical AB. Dr. Lof has been a Di...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Johan Lof	Founder	24.3yrs	kr9.76m	16.51% SEK 68.1m
Bjorn Hardemark	Deputy Chief Executive Officer	8.7yrs	kr3.54m	0.052% SEK 216.4k
Annika Henriksson	Deputy Chief Financial Officer	less than a year	sin datos	sin datos
Kjell Eriksson	Head of Research & Chief Science Officer	8.7yrs	sin datos	0.070% SEK 288.6k
Petra Jansson	General Counsel	6.8yrs	sin datos	sin datos
Peter Kemlin	Director of Sales & Marketing	no data	sin datos	0.0041% SEK 16.8k
Tove Alteborg	Global Human Resource Manager	less than a year	sin datos	sin datos
Fredrik Lofman	Head of Machine Learning	4.3yrs	sin datos	0.0041% SEK 16.8k
Marc Mlyn	President & CEO of RaySearch Americas	2.3yrs	sin datos	sin datos

5.6yrs

Permanencia media

49.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 27R es experimentado (5.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Johan Lof	Founder	24.3yrs	kr9.76m	16.51% SEK 68.1m
Hans Wigzell	Independent Chairman of Board	20yrs	kr840.00k	sin datos
Carl Bergendal	Independent Director	24.3yrs	kr225.00k	3.39% SEK 14.0m
Radhe Mohan	Member of Scientific Advisory Board	21.3yrs	sin datos	sin datos
Anders Forsgren	Member of Scientific Advisory Board	no data	sin datos	sin datos
Anders Brahme	Member of Scientific Advisory Board	no data	sin datos	3.79% SEK 15.6m
David Jaffray	Member of Scientific Advisory Board	no data	sin datos	sin datos
Britta Wallgren	Independent Director	6yrs	kr300.00k	0.020% SEK 84.2k
Gunther Marder	Independent Director	1.5yrs	kr300.00k	0.20% SEK 841.1k

20.7yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 27R son experimentados ( 20.6 años antigüedad media).

RaySearch Laboratories Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold €3.4m worth of stock

Founder recently sold €94k worth of stock

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

Recent updates

First quarter 2024 earnings released: EPS: kr1.07 (vs kr0.51 in 1Q 2023)

Raysearch to Present the Latest Advances in Raystation, Raycare and Rayintelligence At Estro 2024

Full year 2023 earnings released: EPS: kr2.38 (vs kr0.69 in FY 2022)

New major risk - Revenue and earnings growth

RaySearch Laboratories AB (publ) Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024

RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

RaySearch Laboratories AB (publ) Releases Raystation 2024A

Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022)

RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024

RaySearch to Showcase Latest Innovations in Raystation, RayCare and RayIntelligence to Be Presented at ASTRO 2023

RaySearch Laboratories AB (Publ) to Showcase the Latest Software Innovations At Astro in San Diego, California, October 1-4

RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2023 earnings released: EPS: kr0.32 (vs kr0.58 loss in 2Q 2022)

RaySearch Laboratories AB (publ) to Report Q1, 2024 Results on May 17, 2024

RaySearch to Present the Latest Advances in Raystation, RayCare and RayIntelligence at AAPM 2023

RaySearch Laboratories AB (Publ) Announces the Release of the Latest Version of RayCare®, the Next Generation Oncology Information System

New minor risk - Share price stability

RaySearch Laboratories AB (publ) Releases Raystation 2023B

Raysearch Laboratories AB (Publ)'s RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

Henrik Bergentoft Leaves the Position as CFO for Raysearch

New minor risk - Insider selling

Founder recently sold €3.4m worth of stock

New minor risk - Shareholder dilution

RaySearch Laboratories AB (publ) Announce to Exhibit Latest Software Innovations for Particle Therapy and BNCT at PTCOG 2023

First quarter 2023 earnings released

Founder recently sold €94k worth of stock

Full year 2022 earnings released: EPS: kr0.69 (vs kr1.38 loss in FY 2021)

RaySearch Laboratories AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

RaySearch Laboratories AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

Third quarter 2022 earnings released

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Second quarter 2022 earnings released

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

RaySearch Laboratories AB (publ) Launches RayStation 12A

RaySearch to Exhibit the Latest Software Innovations for Particle Therapy at PTCOG 2022

RaySearch Laboratories AB (publ) Releases Latest Version of RayCare

Founder recently sold €1.9m worth of stock

First quarter 2022 earnings released

Raysearch Laboratories AB (Publ) Announces Raystation, Rayintelligence and Raycare to Be Presented At Estro 2022

Insufficient new directors

RaySearch Laboratories AB (publ) Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Founder recently sold €550k worth of stock

RaySearch AB (publ) Provides Cancer Clinics with User Configurable Workflows for Radiation Therapy

RayStation 11B Brings New Features for Adaptive Workflows, Brachytherapy, and Radiation Therapy with Ions

Third quarter 2021 earnings released

RaySearch Laboratories AB (publ) to Showcase Latest Innovations, RayIntelligence and RayCare at ESTRO 2021

Second quarter 2021 earnings released

Insufficient new directors

RaySearch Laboratories AB (Publ) Announces RayStation 9 Granted Regulatory Clearance in China

Raysearch Announces the Release of A New Version of Raycare®, the Next-Generation Oncology Information System

Raysearch Laboratories Announces the Release of Raystation® 11A

Raysearch Laboratories AB (Publ) Provides Earnings Guidance for 2021

RaySearch Laboratories AB (publ) Announces Royal Brisbane and Women's Hospital Treats First Patients Using the Raystation® Treatment Planning System

Full year 2020 earnings released: kr0.26 loss per share (vs kr1.47 profit in FY 2019)

Revenue misses expectations

RaySearch Laboratories AB (publ) to Report First Half, 2021 Results on Aug 25, 2021

New 90-day high: €9.09

RaySearch Laboratories AB (publ) Announces University Medical Center Maribor in Slovenia Became the 700th Customer to Select RayStation

New 90-day high: €8.92

RaySearch Receives New Order from Centre Antoine Lacassagne for RayStation in France

RaySearch Laboratories AB (Publ) Announces the Release of the First Version of the Treatment Control System (TCS) Raycommand

RaySearch Laboratories AB (publ) Announces Expansion of the Advanced Treatment Planning System Raystation

New 90-day high: €8.35

RaySearch Laboratories AB (Publ) Launches Raystation® 10B for Brachytherapy Planning and New Gpu Monte Carlo Algorithm

RaySearch Laboratories AB (publ) Shares News of the Latest Release of Oncology Information System RayCare®

RaySearch Laboratories Introduction of RayIntelligence and the latest releases of RayStation and RayCare at ESTRO 2020